Tianlong Contributes to China’s Power to Prevent and Control Global Epidemics
By LabMedica International staff writers Posted on 02 Jan 2023 |
Since the year 2003, Tianlong Science and Technology (Shaanxi, China) has witnessed several health crises globally and has also contributed to China’s power to prevent and control major epidemics such as COVID-19, SARS, Avian influenza, Ebola, Zika, and African swine fever.
Tianlong is an innovative high-tech company specializing in molecular diagnostic products. Since being founded in 1997, Tianlong has devoted itself to providing integrated PCR lab solutions for professionals worldwide. The company has a wide range of products from devices to reagents, including nucleic acid extractors, real-time PCR systems, all-in-one molecular diagnosis systems, sample processing systems, liquid handling systems, and 300 kinds of compatible reagents.
With NMPA, CE, and FDA marks, Tianlong’s products are exported to more than 100 countries and regions worldwide, and have greatly helped in the prevention and control of epidemics such as COVID-19, SARS, Avian influenza, Ebola, Zika, and African swine fever. Tianlong continues to excel in R&D and bringing technology to life to make people's lives healthier and happier.
Related Links:
Tianlong Science and Technology
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus